Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AC Immune Beefs Up Neurodegenerative Diseases Pipeline

Executive Summary

The Swiss biotech, AC Immune, has identified further antibodies aimed at targets in neurodegenerative diseases that could complement its work in beta-amyloid and tau-based approaches to conditions like Alzheimer's disease.

Advertisement

Related Content

Finance Watch: Summer Heat Extends To Biopharma IPOs With Nine In July, 45 This Year
AZ Partners Parkinson's Compound With Takeda
Alzheimer’s Update: Amyloid Hypothesis Lives On At Biogen, Lilly, Merck, Pfizer, Roche
Bullish Lilly Adds New Alzheimer's Candidate To Clinical Portfolio
IPO Update: Novan, AC Immune End Summer Slowdown As Market Improves

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099365

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel